We are live on
!
Find out more
TA
Tamarack Advisers Portfolio holdings
AUM
$2.12M
1-Year Est. Return
58.09%
This Fund
S&P 500
This Quarter
Est. Return
-2.76%
1 Year Est. Return
-58.09%
3 Year Est. Return
-46.51%
5 Year Est. Return
+44.44%
10 Year Est. Return
–
AUM
$317M
AUM Growth
-$36.3M
(-10%)
Cap. Flow
-$21.4M
Cap. Flow
% of AUM
-6.75%
Top 10 Holdings %
Top 10 Hldgs %
56.14%
Holding
64
New
13
Increased
14
Reduced
15
Closed
19
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Perrigo
PRGO
|
+$8.9M |
| 2 |
CALY
Callaway Golf Company
CALY
|
+$8.67M |
| 3 |
Steris
STE
|
+$7.7M |
| 4 |
Henry Schein
HSIC
|
+$6.54M |
| 5 |
Tenet Healthcare
THC
|
+$5.32M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
UnitedHealth
UNH
|
+$12M |
| 2 |
Viatris
VTRS
|
+$11.7M |
| 3 |
CVS Health
CVS
|
+$8.34M |
| 4 |
Cigna
CI
|
+$8.3M |
| 5 |
Medtronic
MDT
|
+$6.47M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 88.76% |
| 2 | Consumer Staples | 4.15% |
| 3 | Consumer Discretionary | 3.93% |
| 4 | Miscellaneous | 2.04% |
| 5 | Technology | 1.13% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Henry Schein
HSIC
$10B
| $30.5M | 9.62% |
400,000
+85,000
| +27% | +$6.54M |
|
2
Rigel Pharmaceuticals
RIGL
$909M
| $25.4M | 8.02% |
700,000
+60,000
| +9% | +$2.36M |
|
|
3
Medtronic
MDT
$120B
| $25.1M | 7.92% |
200,000
-50,000
| -20% | -$6.47M |
|
4
Pacira BioSciences
PCRX
$1.05B
| $21M | 6.63% |
375,000
+15,000
| +4% | +$865K |
|
|
PDCO
5
DELISTED
Patterson Companies, Inc.
PDCO
| $14.9M | 4.71% |
495,000
+20,000
| +4% | +$607K |
|
6
Turning Point Brands
TPB
$1.51B
| $13.1M | 4.15% |
275,000
-125,000
| -31% | -$5.99M |
|
|
CALY
7
Callaway Golf Company
CALY
$2.84B
| $12.4M | 3.93% |
450,000
+285,000
| +173% | +$8.67M |
|
8
United Therapeutics
UTHR
$20.9B
| $12M | 3.79% |
65,000
+3,000
| +5% | +$591K |
|
|
9
Perrigo
PRGO
$2.07B
| $11.8M | 3.74% |
250,000
+200,000
| +400% | +$8.9M |
|
|
VRAY
10
DELISTED
ViewRay, Inc.
VRAY
| $11.5M | 3.64% |
1,600,000
-400,000
| -20% | -$2.53M |
|
11
Integer Holdings
ITGR
$4.3B
| $11.2M | 3.53% |
125,000
-10,000
| -7% | -$936K |
|
|
MSON
12
DELISTED
Misonix Inc
MSON
| $10.1M | 3.2% |
400,000
+25,000
| +7% | +$619K |
|
13
Lantheus
LNTH
$6.59B
| $10M | 3.16% |
390,000
-60,000
| -13% | -$1.57M |
|
14
AngioDynamics
ANGO
$628M
| $9.08M | 2.87% |
350,000
+50,000
| +17% | +$1.34M |
|
|
STRM
15
DELISTED
Streamline Health Solutions
STRM
| $8.63M | 2.72% |
328,725
| – | – |
|
16
SI-BONE Inc
SIBN
$829M
| $8.57M | 2.71% |
400,000
+145,000
| +57% | +$3.67M |
|
17
ICU Medical
ICUI
$4.19B
| $8.17M | 2.58% |
35,000
+1,000
| +3% | +$210K |
|
18
AtriCure
ATRC
$2.62B
| $8.14M | 2.57% |
117,000
-33,000
| -22% | -$2.54M |
|
|
MDRX
19
DELISTED
Veradigm Inc. Common Stock
MDRX
| $7.69M | 2.43% |
575,000
+125,000
| +28% | +$2.02M |
|
|
20
Steris
STE
$21.9B
| $7.35M | 2.32% |
+36,000
| New | +$7.7M |
|
21
Bioventus
BVS
$961M
| $6.8M | 2.15% |
480,000
+5,000
| +1% | +$76.9K |
|
22
RadNet
RDNT
$5.8B
| $5.57M | 1.76% |
190,000
-35,000
| -16% | -$1.12M |
|
|
23
Tenet Healthcare
THC
$21.3B
| $4.98M | 1.57% |
+75,000
| New | +$5.32M |
|
24
Phreesia
PHR
$679M
| $4.63M | 1.46% |
75,000
-36,800
| -33% | -$2.46M |
|
25
AdaptHealth
AHCO
$866M
| $4.08M | 1.29% |
175,000
-125,000
| -42% | -$3.02M |
|
Similar funds
SCM
LBC
ICM
LCMP
GIP
STC
GC
DU
Tamarack Advisers's Q3 2021 Portfolio in Review
As of Q3 2021, Tamarack Advisers held 64 positions worth $317M, down 10% from $353M the previous quarter. Its ten largest holdings account for 56% of the portfolio.
Tamarack Advisers withdrew a net $21.4M in Q3 2021, closing 19 positions and reducing 15 holdings. Its most notable exit was UnitedHealth, an estimated $12M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 89% of assets, down from 90% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.
Against the trend, Tamarack Advisers opened a new position in Steris worth $7.35M.
- Tamarack Advisers's largest Q3 2021 buy was Steris: 36,000 shares worth $7.35M.
- Tamarack Advisers added most to Perrigo in Q3 2021, an estimated $8.9M increase.
- Tamarack Advisers's biggest Q3 2021 reduction was Medtronic, cutting an estimated $6.47M.
- Tamarack Advisers fully exited UnitedHealth in Q3 2021, selling an estimated $12M.
- Tamarack Advisers's ten largest holdings make up 56% of its $317M portfolio in Q3 2021.
- Tamarack Advisers opened 13 new positions and closed 19 in Q3 2021.
- Tamarack Advisers's portfolio value fell 10% quarter-over-quarter to $317M.
Based on Tamarack Advisers's 13F filing for Q3 2021, filed 12 Nov 2021.